한국 조현병 환자에서 벤조다이아제핀의 사용 : 건강보험심사평가원 자료 분석
Benzodiazepine Use among Patients with Schizophrenia in Korea : Analysis of Database of Health Insurance Review Agency
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective This study was designed to examine the pattern of benzodiazepine use in a representative sample of patients with schizophrenia in Korea. Method Data generated by the Health Insurance Review Agency of Korea was used to examine the frequency of benzodiazepine use. Demographic and geographic factors, hospital types in which patients received prescriptions, health insurance coverage, and the number of concomitant antipsychotics associated with benzodiazepine use were explored by multivariate logistic regression analysis. Results Among the 183427 patients with schizophrenia, the frequency of benzodiazepine use was 67.5% (n=122859). Use of benzodiazepines was highly associated with female patients treated in hospitals located in Gyeonggi, Gyeongsang, and Gangwon provinces, medicaid patients, patients treated in mental hospitals and private psychiatric clinics, and patients using concomitant antipsychotic agents. Conclusion The study demonstrated that benzodiazepine use was highly prevalent among patients with schizophrenia. Long-term use of benzodiazepine may be at higher risk of neurocognitive side effects and risk of mortality. Therefore, patients with schizophrenia taking benzodiazepine concomitantly should be closely monitored for benefits and risks of benzodiazepine use. For the medicaid patients, policy change is urgently needed in order for patients to receive equal quality of treatment with that of non-medicaid patents.
Abstract
Objective This study was designed to examine the pattern of benzodiazepine use in a representative sample of patients with schizophrenia in Korea. Method Data generated by the Health Insurance Review Agency of Korea was used to examine the frequency of benzodiazepine use. Demographic and geographic factors, hospital types in which patients received prescriptions, health insurance coverage, and the number of concomitant antipsychotics associated with benzodiazepine use were explored by multivariate logistic regression analysis. Results Among the 183427 patients with schizophrenia, the frequency of benzodiazepine use was 67.5% (n=122859). Use of benzodiazepines was highly associated with female patients treated in hospitals located in Gyeonggi, Gyeongsang, and Gangwon provinces, medicaid patients, patients treated in mental hospitals and private psychiatric clinics, and patients using concomitant antipsychotic agents. Conclusion The study demonstrated that benzodiazepine use was highly prevalent among patients with schizophrenia. Long-term use of benzodiazepine may be at higher risk of neurocognitive side effects and risk of mortality. Therefore, patients with schizophrenia taking benzodiazepine concomitantly should be closely monitored for benefits and risks of benzodiazepine use. For the medicaid patients, policy change is urgently needed in order for patients to receive equal quality of treatment with that of non-medicaid patents.
참고문헌 (25)
- American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders: DSM-5", pp.99~105 (2013), American Psychiatric Publishing
- clinical psychiatry, "Synopsis of psychiatry: behavioral sciences", pp.2014, Sadock BJ
- Korean medication guideline for schizophrenia, "Kwon JS", Korean Medication Algorithm Task Force for Schizophrenia, ~ (2006)
- Haw C, "Benzodiazepines--a necessary evil? A survey of prescribing at a specialist UK psychiatric hospital", J Psychopharmacol, 21, pp.645~649 (2007)
- Wolkowitz OM, "Benzodiazepines in the treatment of schizophrenia:a review and reappraisal", Am J Psychiatry, 148, pp.714~726 (1991)
- Chakos MH, "Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial", Psychiatr Serv, 57, pp.1094~1101 (2006)
- Novick D, "Use of concomitant medication with antipsychotic treatment in outpatients with schizophrenia: results from the European Schizophrenia Outpatients Health Outcomes (SOHO) study", Prog Neuropsychopharmacol Biol Psychiatry, 29, pp.972~982 (2005)
- Clark RE, "Benzodiazepine prescription practices and substance abuse in persons with severe mental illness", J Clin Psychiatry, 65, pp.151~155 (2004)
- Wu CS, "Benzodiazepine use among patients with schizophrenia in Taiwan: a nationwide population-based survey", Psychiatr Serv, 62, pp.908~914 (2011)
- 황인환, "조현병 환자의 입원 치료시 약물처방 경향의 변화 : 일 대학병원에서 1996~2000년과 2006~2010년의 차이 비교", 생물정신의학, 21(2), pp.49~56 (2014), 대한생물정신의학회
- Dold M, "Benzodiazepines for schizophrenia", Cochrane Database Syst Rev, 11, pp.CD006391~ (2012)
- Brunette MF, "Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders", Psychiatr Serv, 54, pp.1395~1401 (2003)
- Dixon L., "Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes", Schizophr Res, 35(Suppl), pp.S93~S100 (1999)
- Green MF, "Cognitive impairment and functional outcome in schizophrenia and bipolar disorder", J Clin Psychiatry, 67, pp.e12~ (2006)
- Liu SK, "Deficits in sustained attention in schizophrenia and affective disorders: stable versus state-dependent markers", Am J Psychiatry, 159, pp.975~982 (2002)
- Baandrup L, "Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested casecontrol study", J Clin Psychiatry, 71, pp.103~108 (2010)
- Tiihonen J, "Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia", Arch Gen Psychiatry, 69, pp.476~483 (2012)
- Fontanella CA, "Benzodiazepine use and risk of mortality among patients with schizophrenia: a retrospective longitudinal study", J Clin Psychiatry, 77, pp.661~667 (2016)
- Tiihonen J, "Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study", Am J Psychiatry, 173, pp.600~606 (2016)
- 김록영, "입원 환자 표본 개발에 관한 연구: 국민건강보험 청구자료를 중심으로", 보건행정학회지, 23(2), pp.152~161 (2013), 한국보건행정학회
- WHO Collaborating Centre for Drug Statistics Methodology, "Guidelines for ATC classification and DDD assignment", WHO Collaborating Centre for Drug Statistics Methodology, ~ (2009)
- Baldwin DS, "Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology", J Psychopharmacol, 19, pp.567~596 (2005)
- 정성훈, "리스페리돈과 올란자핀을 사용한 정신분열병 환자 치료 패턴의 변이 조사", 신경정신의학, 42(1), pp.79~88 (2003), 대한신경정신의학회
- National mental health statisticspilot study, "National Center for Mental Health", National Center for Mental Health, ~ (2016)
- National report for human rights protection and enhancement of people with mental disabilities, "National Human Rights Commission of Korea", National Human Rights Commission of Korea, ~ (2009)